RxDoctor Payments DataLook up a doctor →

Mitchell Isaac, MD

Neurology · Winston Salem, NCNPI 1629283908

Payments from drug & device makers

$2,159,674in general payments, 2019–2025

Across 298 payments — averaging $7247.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$1.4M
  • Biogen$353K
  • AbbVie$302K
  • H. Lundbeck A S$52K
  • Novartis$29K
  • Pfizer$16K
  • plus $40K from 18 others
$4,943in research payments, 2019–2025

Across 8 payments — averaging $617.89 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$5K

What the payments were for

  • Consulting fees$18,09447%
  • Speaking & faculty fees$11,62531%
  • Travel & lodging$2,6327%
  • Food & beverage$5,59015%
  • Education$1690%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,159,674 in reported general payments places this provider in the 95th percentile of 566 neurology providers in North Carolina.

See all neurology providers in North Carolina

Medicare billing

Part B allowed, 2024
$410,811
Medicare patients
462
Services billed
27,875

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gamunex-CImmune Globul G/Gly/Iga Avg 4635$485,578
Aimovig AutoinjectorErenumab-Aooe193$173,196
Nurtec OdtRimegepant Sulfate80$128,911
Austedo XrDeutetrabenazine11$117,160
ZeposiaOzanimod Hydrochloride13$115,568
TysabriNatalizumab13$105,874
IngrezzaValbenazine Tosylate13$104,556
BotoxOnabotulinumtoxina61$96,775
Emgality PenGalcanezumab-Gnlm113$91,812
CopaxoneGlatiramer Acetate12$70,004
UbrelvyUbrogepant41$50,412
QuliptaAtogepant47$49,930
Gabapentin794$16,987
Keppra XrLevetiracetam12$12,250
Duloxetine Hcl415$11,408

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieBotox, Ubrelvy, Qulipta, Linzess$302,092$203,354161 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr, Copaxone$180$187,16423 claims
PfizerNurtec Odt$15,621$128,91180 claims
E.r. Squibb & Sons, L.L.C.Zeposia$76$115,56813 claims
BiogenTysabri$353,253$105,87413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 566 neurology providers in North Carolina.

Other neurology in Winston Salem

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →